Diligence memo · auto-generated · as of July 2, 2026
DxNA LLC
DxNA LLC looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
DxNA LLC operates in Biotechnology, based in ST. GEORGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
DxNA LLC has raised $9.0M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on —.
Most recent recorded round closed around 2013-12-30.
Valuation (modeled)modeled
Provath models DxNA LLC at approximately $167M (range $2.7M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.05× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 264 months.
Last raise 12.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 13.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 54% of Biotechnology peers (4293 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.